GlassScriptPhysician profile
William A Kay
NPI 1700094307
$3,813.76
in general payments reported to CMS, 2019-2025
25 companies · $349 in 2025
The $349 reported for 2025 was more than what a typical Adult Congenital Heart Disease provider received nationally (typical 2025 total: $272).
See the full distribution for Adult Congenital Heart Disease
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.98 · 2020: $192 · 2021: $277 · 2022: $1,713 · 2023: $1,058 · 2024: $206 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $665.05 | 2020-2025 | |
| Amgen INC. | $593.05 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $363.28 | 2021-2024 | Watchman Access System, Rotapro |
| Abbott Laboratories | $294.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.21 | 2021-2023 | Jardiance |
| Edwards Lifesciences Corporation | $198.99 | 2025 | Sapien 3 Ultra Resilia |
| Pfizer INC. | $152.16 | 2019-2023 | |
| Atricure, INC. | $147.59 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $137.74 | 2021-2023 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $122.93 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $111.91 | 2022 | |
| United Therapeutics Corporation | $100.00 | 2020 | |
| Medtronic, INC. | $99.47 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $73.59 | 2021-2023 | Lifevest |
| Daiichi Sankyo INC. | $73.36 | 2022-2023 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.88 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $63.29 | 2021-2023 | Farxiga |
| Philips North America LLC | $57.11 | 2022-2024 | (Ck7) Extended Holter |
| Amarin Pharma, INC. | $51.97 | 2021-2023 | |
| Lexicon Pharmaceuticals, INC. | $49.48 | 2023 | Inpefa |
| Cvrx, INC. | $41.39 | 2022-2023 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $27.65 | 2021-2025 | Camzyos |
| Novo Nordisk INC | $23.38 | 2023 | Ozempic |
| Kiniksa Pharmaceuticals, LTD. | $18.48 | 2023 | Arcalyst |
| Chiesi USA, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.